Review Question - QID 211453

A patient with known Marfan syndrome presents to clinic for follow up evaluation. They have been previously diagnosed with an aortic aneurysm that is being managed by another provider with beta-blockers. They discuss with you that this provider was considering switching the patient to a different class of medication. You educate the patient on the pathophysiology of their disease and why the provider may be considering this medication. What two factors are thought to work synergistically in the pathologic development of aortic aneurysms secondary to Marfan syndrome?